Moderna's COVID-19 vaccine generated a "strong immune response" among children between the ages of 6 and 11, the company has announced.
Moderna revealed the interim results from a trial consisting of 4,753 participants between the ages of 6 and 11, and it said the vaccine was well-tolerated and generated a strong immune response, CNN reports. "The majority of adverse events were mild or moderate in severity," the company said. In the trial, two doses were given to children 28 days apart. The children received smaller doses than adults.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
What could bring the US Steel-Nippon Steel merger back to life?Today's Big Question President Trump opposed the deal. But he could be flexible.
-
'Orange juice also is facing a grander existential problem'Instant Opinion Opinion, comment and editorials of the day
-
5 of the scariest spiders in existenceThe Explainer These creepy crawlers can be deadly
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
How close are we to a norovirus vaccine?Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
-
HMPV is spreading in China but there's no need to worryThe Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDAIn the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
-
California declares bird flu emergencySpeed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
